CHRONIC HEPATITIS B: AN OVERVIEW

Prof. Mobin Khan
MBBS (Dhaka), MSc (Queensland), FCPS (BD), FCPS (Pak) FACP (USA), FCCP (USA), FRCP (Edin), FRCP (Glasgow)
Chairman
Department of Hepatology
Bangabandhu Sheikh Mujib Medical University, Dhaka
E-mail : mobin@bdonline.com
Website : www.profmobinkhan.com

Dr. M G Azam
 MBBS (DMC), MD (Hepatology, DU)
Specialist in Liver Diseases
BIRDEM Hospital, Dhaka
Recipient of "Certificate of Distinction"
Awarded by The American Association for the Study of Liver Diseases & Asian Pacific Association for the Study of the Liver
E-mail : mgazam@yahoo.com

   

Viral hepatitis is the commonest liver disease in Bangladesh. About one crore people in Bangladesh have been suffering from hepatitis B. A proportion of them are hepatitis B carrier and another proportion is affected by the long-standing consequences of this infection. The treatment of hepatitis B possess a great challenge. Enumerable authors working to find out cheap, effective, efficient and easily administered drug therapy for chronic hepatitis B (CHB).

The present paper highlights the recent advances in the management of chronic hepatitis B and overview the pros and cons of currently available drug therapy.

INTRODUCTION TO HEPATITIS B VIRUS

Hepatitis B virus (HBV) belongs to hepadnaviridae family which primarily infects liver cells. The HBV genome is a relaxed circular, partially double stranded DNA of approximately 3,200 base pairs.

The replication cycle of HBV begins with the attachment of the virion to the hepatocyte. Inside the hepatocyte nucleus, synthesis of the plus strand HBV DNA is completed and the viral genome is converted into a covalently closed circular DNA (cccDNA).

The cccDNA is the template for the pregenomic RNA, which is reverse transcribed into the minus strand HBV DNA. There are two sources of cccDNA: entry of new virus particles into the hepatocyte and translocation of newly synthesized HBV DNA from the hepatocyte cytoplasm (Fig. 1). Most antiviral agents that have been examined so far have little or no effect on cccDNA.1 This accounts for the rapid

reappearance of serum HBV DNA after cessation of antiviral therapy.

HBV is 100 times more infective than human immunodeficiency virus (HIV). It is found in blood and body fluids and able to survive in dried blood for longer than 1 week. It can be transmitted by inoculation with contaminated blood or blood products, by sexual contact, by transplantation of organs from infected donors, by sharing contaminated needles, syringes, razors, blades, tooth brush etc. and perinatally form infected mothers. There is no evidence of viral transmission through breast milk.2 In about one third cases, the underline mode of transmission is not known.